伊格列净治疗2型糖尿病的Meta分析

发布时间：2018-08-02 20:36

【摘要】：目的系统评价伊格列净治疗2型糖尿病的疗效和安全性。方法计算机检索PubMed、Cochrane Library、Embase、中国知网、万方医学网、维普全文数据库、中国生物医学文献数据库等,获取伊格列净治疗2型糖尿病的随机对照试验(RCT),检索时限均为建库至2017年2月,并追溯纳入文献的参考文献,由2位研究员根据纳入与排除标准筛选试验、提取资料、评价文献质量并交叉核对结果,采用RevMan5.20软件对各项指标进行Meta分析。结果共纳入7篇RCT,1 267例2型糖尿病患者,Meta分析结果显示,伊格列净组在糖化血红蛋白(HbA1c)、HbA1c7%达标率及体重控制方面均优于对照组,差异有显著意义[MD=-0.98,95%CI(-1.20,-0.77),P0.01;OR=3.99,95%CI(2.69,5.91),P0.01;MD=-1.70,95%CI(-2.28,-1.12),P0.01]。在安全性方面,伊格列净组严重不良反应、低血糖、尿路感染、生殖器感染的发生率与对照组相当,差异无显著意义[OR=0.48,95%CI(0.22,1.07),P=0.07;OR=1.57,95%CI(0.43,5.71),P=0.49;OR=1.22,95%CI(0.59,2.52),P=0.59;OR=1.14,95%CI(0.41,3.21),P=0.8]。结论伊格列净能较好控制2型糖尿病患者的HbA1c和体重,不良反应发生率低,安全性较高。
[Abstract]:Objective to evaluate the efficacy and safety of Eaglidine in the treatment of type 2 diabetes mellitus. Methods the (RCT), retrieval time of the randomized controlled trial (RCT),) for the treatment of type 2 diabetes mellitus was obtained by computer search of PubMedus Cochrane Library Embase, China knowledge Network, Wanfang Medical Network, Weip Full-text Database, Chinese Biomedical Literature Database, etc. The time limit for obtaining the search time was until February 2017. According to the criteria of inclusion and exclusion, the data were extracted, the quality of the literature was evaluated and the results were cross-checked. The Meta analysis of each index was carried out by RevMan5.20 software. Results Meta-analysis of 1 267 patients with type 2 diabetes mellitus included seven RCTs. The results showed that Iglablagline group was superior to the control group in HbA1c HbA1c7% reaching standard rate and body weight control, and the difference was significant (MD-0.9895 CI (-1.20-0.77), P0.01 OR3.995 CI (2.69 卤5.91), P0.01MD-1.7095CI (-2.28-1.12) P0.01). In terms of safety, the incidence of severe adverse reactions, hypoglycemia, urinary tract infection and genital infection in the Iglijing group was similar to that in the control group, and there was no significant difference between the two groups. Conclusion Eaglidine can control HbA1c and body weight of type 2 diabetic patients with low incidence of adverse reactions and high safety.
【作者单位】：西南医科大学药学院;川北医学院药学院;重庆三峡中心医院药学部;
【基金】：重庆市社会事业与民生保障科技创新专项(cstc2015shmszx120073) 重庆市万州区科技计划基金资助项目(201403055)
【分类号】：R587.1

【相似文献】